Rhetorical Strategies Used in the Reporting of Implantable Defibrillator Primary Prevention Trials

被引:7
|
作者
Wilson, John R.
机构
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 107卷 / 12期
关键词
CARDIOVERTER-DEFIBRILLATOR; DILATED CARDIOMYOPATHY; PROPHYLACTIC USE; HIGH-RISK; AMIODARONE; DEATH;
D O I
10.1016/j.amjcard.2011.02.320
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous studies have suggest that the authors of randomized trial reports frequently use rhetorical strategies, such as framing, the use of ratios rather than absolute values to report results, and underreporting of complications, to convince readers of treatment efficacy. The objective of this study was to determine if such rhetorical strategies were used in the publication of implantable-cardioverter defibrillator (ICD) primary prevention trials. Med-line and the Cochrane Central Register Of Controlled Trials were searched for all publications that described ICD primary prevention trials and that involved > 100 subjects. Each publication was analyzed for evidence of message framing, the exclusive use of ratios to report outcomes, underreporting of ICD complications, and interpretation bias favoring ICD therapy. Ten publications were identified. Introductory remarks in 8 of the 10 publications cited the evaluation of ICD benefits as the sole objective and mentioned only background studies that supported ICD efficacy, suggesting message framing in support of ICD efficacy. Five publications provided no specific information about the frequency of unsuccessful ICD implantations, and 8 publications provided incomplete or no information about implantation and postimplantation complications. ICD complications were not mentioned in the discussion sections of 9 publications, and none of the publications included a comprehensive comparison of ICD benefits versus risks, consistent with interpretation bias. Ratios and statistically insignificant data were not used to emphasize ICD benefits. In conclusion, message framing, underreporting of ICD complications, and interpretation bias were used to emphasize ICD efficacy in the reporting of ICD primary prevention trials. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1806-1811)
引用
收藏
页码:1806 / 1811
页数:6
相关论文
共 50 条
  • [41] Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy
    Maron, Barry J.
    Maron, Martin S.
    HEART RHYTHM, 2016, 13 (05) : 1155 - 1165
  • [42] Questioning the preference for dual- vs. single-chamber implantable defibrillator in primary prevention implantable cardioverter-defibrillator recipients
    Kutyifa, Valentina
    Theuns, Dominic A. M. J.
    EUROPACE, 2017, 19 (09): : 1416 - 1417
  • [43] Psychological adjustment in patients with an implantable cardioverter defibrillator primary prevention and secondary prevention. A comparative study
    Alcaraz Andreu, Silvia
    Hidalgo Montesinos, Maria Dolores
    Godoy Fernandez, Carmen
    Fernandez Ros, Encarna
    Sanchez Munoz, Juan Jose
    Garcia Alberola, Arcadio
    REVISTA ESPANOLA DE SALUD PUBLICA, 2020, 94
  • [44] Implantable cardioverter defibrillator - powerful weapon in primary and secondary prevention of sudden cardiac death
    Kostic, Tomislav
    Stanojevic, Dragana
    Gudelj, Ognjen
    Milic, Dragan
    Putnik, Svetozar
    Perisic, Zoran
    Djindjic, Boris
    Pavlovic, Milan
    Koracevic, Goran
    Golubovic, Mladjan
    Mitov, Vladimir
    Momcilovic, Stefan
    Bankovic, Sanja
    VOJNOSANITETSKI PREGLED, 2019, 76 (10) : 1007 - 1013
  • [45] Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy
    Nauffal, Victor
    Marstrand, Peter
    Han, Larry
    Parikh, Victoria N.
    Helms, Adam S.
    Ingles, Jodie
    Jacoby, Daniel
    Lakdawala, Neal K.
    Kapur, Sunil
    Michels, Michelle
    Owens, Anjali T.
    Ashley, Euan A.
    Pereira, Alexandre C.
    Rossano, Joseph W.
    Saberi, Sara
    Semsarian, Christopher
    Ware, James S.
    Wittekind, Samuel G.
    Day, Sharlene
    Olivotto, Iacopo
    Ho, Carolyn Y.
    EUROPEAN HEART JOURNAL, 2021, 42 (38) : 3932 - 3944
  • [46] The prognostic value of electrocardiographic alternans in the primary prevention on patients having an implantable cardioverter defibrillator
    Iammarino, Erica
    Marcantoni, Ilaria
    Sbrollini, Agnese
    Morettini, Micaela
    Swenne, Cees A.
    Burattini, Laura
    2024 IEEE INTERNATIONAL SYMPOSIUM ON MEDICAL MEASUREMENTS AND APPLICATIONS, MEMEA 2024, 2024,
  • [47] Should the Subcutaneous Implantable Defibrillator Be the First Choice for Primary Prevention of Sudden Cardiac Death?
    Knops, Reinoud E.
    Brouwer, Tom F.
    REVISTA ESPANOLA DE CARDIOLOGIA, 2017, 70 (03): : 142 - 144
  • [48] Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention
    Ascoeta, Maria Soledad
    Marijon, Eloi
    Defaye, Pascal
    Klug, Didier
    Beganton, Frankie
    Perier, Marie-Cecile
    Gras, Daniel
    Algalarrondo, Vincent
    Deharo, Jean-Claude
    Leclercq, Christophe
    Fauchier, Laurent
    Babuty, Dominique
    Bordachar, Pierre
    Sadoul, Nicolas
    Boveda, Serge
    Piot, Olivier
    HEART RHYTHM, 2016, 13 (05) : 1045 - 1051
  • [49] Is there a role to implantable cardioverter defibrillator for primary prevention in non-ischemic dilated cardiomiopathy?
    Neiva, J. N.
    Rodrigues, I. R.
    Cunha, P. S. C.
    Valente, B. V.
    Nogueira Da Silva, N. S.
    Pimenta, R. P.
    Delgado, A. S. D.
    Bras, M. B.
    Ferreira, R. C. F.
    Oliveira, M. O.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1228 - 1228
  • [50] Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death among Patients With Cancer
    Zadok, Osnat Itzhaki Ben
    Agmon, Inbar Nardi
    Neiman, Victoria
    Eisen, Alon
    Golovchiner, Gregory
    Bental, Tamir
    Schamroth-Pravda, Nili
    Kadmon, Ehud
    Goldenberg, Gustavo Ruben
    Erez, Aharon
    Kornowski, Ran
    Barsheshet, Alon
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 191 : 32 - 38